BioSpace News Archive

Poseida Therapeutics, Inc. (Nasdaq: PSTX) today announced that the Company’s President and Chief Executive Officer, Kristin Yarema, Ph.D., will participate in a virtual fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, 2024 at 1:00pm PT | 4:00pm ET.

Longeveron Inc. announced that the Company’s Board of Directors has approved a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share .

Tyra Biosciences, Inc. (Nasdaq: TYRA) today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted recent corporate progress.

Debbie’s Dream Foundation: Curing Stomach Cancer announces an unprecedented collaboration with Memorial Sloan Kettering Cancer Center that marks a significant leap forward in the field of gastric cancer research.

Delcath Systems, Inc. announced today it will host a conference call on March 26, 2024 , at 8:30 AM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023 and provide a business update.

Lavie Bio Ltd., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products and a subsidiary of Evogene Ltd., announced that it is extending its joint validation trials for its biofungicides conducted by Bayer AG, a global leader in the agriculture industry, after successful first-year laboratory and greenhouse testing.

Adela, Inc. today announced data will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 5-10, 2024 from its tissue-agnostic minimal residual disease (MRD) assay.

Verb Biotics today announced preliminary preclinical data from their newly launched Keystone Postbiotic™, a foundational gut microbiome solution to help support and strengthen gut microbiome health.

CEL-SCI Corporation (NYSE American: CVM) today announced the peer reviewed scientific journal Frontiers in Immunology published an article regarding CEL-SCI’s Ligand Epitope Antigen Presentation System (LEAPS).

LIB Therapeutics, Inc. today announced that its regional partner in China, Hasten Biopharmaceuticals Co, Ltd. (Hasten), has received notification of acceptance for the clinical trial application for Lerodalcibep by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China.